Viatris VTRS 深滬

等待開盤 10-08 09:30:00 美东时间

17.49

-0.050

-0.29%

華盛通

立即下載

最高17.815
今開17.52
成交量 754.39万股
最低 17.41
昨收 17.54
總市值 200.89亿
52周最高 18.43
市盈率 ^靜 --
換手率 0.66%
52周最低 9.44
委比 -76.81%
總股本 11.49亿
歷史最高 18.43
量比 0.91
振幅 2.31%
歷史最低 6.13
每手 1
風險率 2.59%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级

今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元

10-06 16:45
UBS Maintains Buy on Viatris, Raises Price Target to $26

UBS analyst Ashwani Verma maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $23 to $26.

10-06 04:43
Harrow Closes TYRVAYA Acquisition, Expanding Dry Eye Portfolio

Harrow Health ( ($HROW) ) has shared an announcement. On October 1, 2026, Harro...

10-05 19:57
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

PITTSBURGH, Oct. 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report third-quarter 2026 financial results on Thursday, November 5...

10-05 18:59
Harrow Closes Acquisition of TYRVAYA®

Harrow acquired TYRVAYA, the first FDA-approved nasal spray for dry eye disease (DED), expanding its ocular surface franchise. TYRVAYA, a cholinergic agonist, stimulates basal tear production via the trigeminal parasympathetic pathway and is approved in the U.S., China, and Taiwan. The acquisition includes worldwide rights except Japan, with Viatris retaining commercialization rights there. Harrow paid $30 million upfront, with up to $70 million ...

10-05 11:00
Stock index futures tick higher ahead of jobs report

Stock index futures rose before the bell as investors braced for the September nonfarm payrolls report, with economic data resilience remaining a key driver of market sentiment. Nasdaq 100 futures (US...

10-02 15:41
Teva wins biosimilar approval of Amgen's Xgeva

The US FDA approved Teva Pharmaceutical Industries' (TEVA) Degvema (denosumab-adet), a biosimilar to Amgen's (AMGN) Xgeva (denosumab), which is indicated to prevent bone damage and complications in ca...

09-29 04:57
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal

Zymeworks Inc. (NASDAQ:ZYME) on Monday finalized its acquisition of Theravance Biopharma, releasing final transaction details and updated financial guidance for fiscal year 2026. The biotechnology company projects 2026 revenue between $278 million and $292 million, alongside 2026 adjusted EBITDA ran...

09-29 01:05
Zymeworks outlines guidance following Theravance acquisition

Zymeworks (ZYME) Monday reported the final transaction details and updated financial guidance following the completion of its acquisition of Theravance Biopharma. The acquisition adds YUPELRI (revefen...

09-28 18:51
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多

今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元

09-24 16:10

派息除權日	每股總股息	派息日期
2026-08-21	0.12	2026-09-16
2026-05-22	0.12	2026-06-17
2026-03-09	0.12	2026-03-18
2025-11-24	0.12	2025-12-15
2025-08-22	0.12	2025-09-15
2025-05-23	0.12	2025-06-16
2025-03-10	0.12	2025-03-18
2024-11-22	0.12	2024-12-13
2024-08-23	0.12	2024-09-13
2024-05-23	0.12	2024-06-14
2024-03-08	0.12	2024-03-18
2023-11-22	0.12	2023-12-15
2023-08-23	0.12	2023-09-15
2023-05-23	0.12	2023-06-16
2023-03-08	0.12	2023-03-17
2022-11-22	0.12	2022-12-16
2022-08-23	0.12	2022-09-16
2022-05-23	0.12	2022-06-16
2022-02-23	0.12	2022-03-16
2021-11-22	0.11	2021-12-16
2021-08-23	0.11	2021-09-16
2021-05-21	0.11	2021-06-16
2007-06-27	0.06	2007-07-16
2007-03-28	0.06	2007-04-16
2006-12-27	0.06	2007-01-16
2006-09-27	0.06	2006-10-16
2006-06-28	0.06	2006-07-14
2006-03-29	0.06	2006-04-17
2005-12-28	0.06	2006-01-13
2005-09-28	0.06	2005-10-17
2005-06-28	0.06	2005-07-15
2005-03-29	0.03	2005-04-15
2004-12-29	0.03	2005-01-14
2004-09-28	0.03	2004-10-15
2004-06-28	0.03	2004-07-15
2004-03-29	0.03	2004-04-15
2003-12-29	0.03	2004-01-15
2003-09-26	0.03	2003-10-15
2003-06-26	0.03	2003-07-15
2003-03-27	0.03	2003-04-15
2002-12-27	0.05	2003-01-15
2002-09-26	0.04	2002-10-15
2002-06-26	0.04	2002-07-15
2002-03-26	0.04	2002-04-15
2001-12-27	0.04	2002-01-15
2001-09-26	0.04	2001-10-15
2001-06-27	0.04	2001-07-16
2001-03-28	0.04	2001-04-16
2000-12-27	0.04	2001-01-15
2000-09-27	0.04	2000-10-15
2000-06-28	0.04	2000-07-15
2000-03-29	0.04	2000-04-15
1999-12-29	0.04	2000-01-14
1999-09-28	0.04	1999-10-15
1999-06-28	0.04	1999-07-15
1999-03-29	0.04	1999-04-15
1998-12-29	0.04	1999-01-15
1998-09-28	0.04	1998-10-15
1998-06-26	0.04	1998-07-15
1998-03-30	0.04	1998-04-15
1997-12-29	0.04	1998-01-15
1997-09-26	0.04	1997-10-15
1997-06-26	0.04	1997-07-15
1997-03-26	0.04	1997-04-15
1996-12-30	0.04	1997-01-15
1996-09-26	0.04	1996-10-15
1996-06-26	0.04	1996-07-15
1996-03-27	0.04	1996-04-15
1995-12-27	0.04	1996-01-15
1995-09-27	0.04	1995-10-13
1995-06-29	0.05	1995-07-14
1995-03-27	0.05	1995-04-13
1994-12-23	0.05	1995-01-13
1994-09-26	0.05	1994-10-14
1994-06-24	0.04	1994-07-15
1994-03-25	0.04	1994-04-15
1993-12-27	0.04	1994-01-14
1993-09-24	0.04	1993-10-15
1993-06-24	0.03	1993-07-15
1993-03-25	0.03	1993-04-15
1992-12-24	0.03	1993-01-15
1992-09-24	0.03	1992-10-15
1992-06-24	0.05	1992-07-15
1992-03-25	0.05	1992-04-15
1991-12-24	0.05	1992-01-15
1991-09-24	0.05	1991-10-15
1991-06-23	0.05	1991-07-14
1991-03-22	0.05	1991-04-14
1990-12-24	0.05	1991-01-15
1990-09-24	0.05	1990-10-15
1990-06-24	0.05	1990-07-15
1989-12-22	0.05	1990-01-15
1989-06-25	0.05	1989-07-16
1988-12-23	0.05	1989-01-16
1988-06-28	0.05	1988-07-14
1987-12-24	0.05	1988-01-15
1987-06-23	0.05	1987-07-14
1986-12-24	0.05	1987-01-15
1986-06-23	0.05	1986-07-14
1985-12-27	0.05	1986-01-15
1985-06-24	0.05	1985-07-19
1984-12-24	0.10	1985-01-15
1984-05-21	0.05	1984-06-13
1983-07-11	0.05	1983-08-12
1981-11-16	1.00	1981-11-13

公司名稱	Viatris
行業分類	--
業務描述	Viatris Inc.于2019年2月14日在特拉华州成立。该公司的业务在医药产品的商业化和制造方面处于全球领先地位，拥有20个全球公认的医药品牌以及一个美国的仿制药平台Greenstone。

Viatris VTRS 深 滬

17.49

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

Viatris VTRS 深滬